2 July 2024 in Український радіологічний та онкологічний журнал
Background. The targeted search for new effective radioprotective agents, especially among compounds with antioxidant properties, remains relevant. Among them, quercetin which has a high specific activity against oxidative stress (cited as a «universal antioxidant») deserves attention. The transport liposomal composition of quercetin, which significantly improves its bioavailability and is the basis of the licensed drug «Lipoflavon®» (LF), is known, but the radioprotective properties of this drug have not been studied. The purpose of the work is to position Lipoflavon as a radioprotector for the first time based on the study of radioprotective activity in an acute experiment with total irradiation of rats. Materials and methods. The rat model of acute radiation syndrome (ARS) was carried out by short-term bilateral total body irradiation (TBI) on a CLINAC (6 MeV) linear accelerator at doses of 5.5 and 7.0 Gy. The control rats were sham-irradiated. The test sample of LF was used for the studies. LF (1.5 mg/mL) was administered to rats 30 min before TBI through the tail vein. The control TBI rats were injected with physiological saline. Experimental rats were randomly assigned into groups as follows: group 1 – non-irradiated control (intact animals); group 2 – irradiated control at a dose of 5.5 Gy (TBI5.5); group 3 – irradiation at a dose of 5.5 Gy with administration of LF (LF + TBI5.5); group 4 – irradiated control at a dose of 7.0 Gy (TBI7.0); group 5 – irradiation at a dose of 7.0 Gy with administration of LF (LF + TBI7.0). Clinical characteristics of ARS, overall survival, and the mean survival time of the dead animals were determined. The profiles of lethality («peaks of death») were calculated as total rat lethality (%) in certain time periods of the ARS. In hematological studies, LF was administered 24 h prior to TBI and twice a week the next 4 weeks after TBI. The hematological parameters were monitored on days 3, 7, 14 and 21 after TBI. Results. It was established that prophylactic LF administered 30 min before TBI at doses of 5.5 and 7.0 Gy, which were LD20/30 and DL73.3/30, increased the 30-day survival rate of the irradiated rats to 90 and 40% respectively, compared to 80 and 26.7% in irradiated control, and changed the radiation lethality profile of the rats in the model of ARS. The radioprotective activity of LF manifested in the form of the absence of early and late peaks of death of the irradiated rats and the survival time of more than 30 days after the treatment in 40% of rats with LD73,3/30. Prophylactic and therapeutic administration of LF prevented development of severe leukopenia and thrombocytopenia and contributed to a more rapid and sustained recovery of erythrocytes during the period of ARS. The most efficient radioprotective therapeutic effect of LF was observed in rats with a dose of LD73.3/30. Conclusions. The results of the study substantiate the radioprotective activity of Lipoflavon in ARS and help develop the new approaches to using the licensed drug «Lipoflavon®» as an effective pharmacological therapeutic agent for radiation protection in acute radiation.
25 December 2025 in Modern medical technology
Predictive justification and experimental confirmation of the pharmacotherapeutic effect of quercetin incorporated into the phosphatidylcholine liposomes or the povidone matrix in a model of acute respiratory distress syndrome induced by intratracheal aspiration of hydrochloric acid are presented. Aim. To establish the phenomenon of the pharmacotherapeutic action of quercetin in transport systems in acute respiratory distress syndrome caused by acid aspiration, using various methods of administration in order to provide experimental justification for the broader clinical translation of known quercetin formulations. Materials and methods. The study was conducted in compliance with bioethical standards using Balb/c mice (25–30 g, both sexes) from the vivarium of the State Institution “Institute of Pharmacology and Toxicology of the National Academy of Medical Sciences of Ukraine”. Acute respiratory distress syndrome (ARDS) was modeled by intratracheal instillation of 0.1 N HCl after propofol anesthesia. Control animals received sterile saline. Two drugs were studied: Lipoflavon® (liposomal quercetin formulation) and Corvitin® (water-soluble quercetin derivative). The samples were administered intravenously and/or by inhalation according to different regimens for 5 days. Therapeutic efficacy was assessed by survival, body weight dynamics, clinical status, and histological examination of lungs and heart. Tissue samples were fixed in formalin, paraffin-embedded, sectioned, stained with hematoxylin-eosin, and examined by light microscopy. Statistical analysis was performed using the Shapiro–Wilk normality test, one-way analysis of variance (ANOVA), or Kruskal–Wallis criterion (p ≤ 0.05). The analysis was performed in Microsoft Excel and using the Statistics Kingdom online calculator. Results. The phenomenon of the therapeutic and prophylactic effect of the studied quercetin transport systems (drugs Lipoflavon and Corvitin) was established in terms of their protective effect on the dynamics of survival (growth up to 100 %), normalization of the clinical condition and weight of animals during ARDS induction by acid aspiration. The pharmacotherapeutic effect of inhalation and injection administration of the studied quercetin preparations was visualized by the histo-morphological picture of structural restoration and anti-inflammatory process in the target lungs and bronchi, which are deeply affected in the ARDS model. Conclusions. The obtained experimental results should contribute to the justification of the clinical translation of drugs based on quercetin transport systems in the medical technology of ARDS treatment.
30 April 2026 in Biotechnologia Acta
Quercetin is a well-known natural antioxidant with a wide spectrum of pharmacological activities, including in oncology, cardiology, ophthalmology, and other areas. Quercetin's lipophilic nature limits its clinical use and necessitates the development of effective delivery systems. Liposomal forms of quercetin are being actively studied and improved. Aim. The article analyzes modern research on liposomal formulations of quercetin as a promising drug-delivery strategy. Materials and methods. Analysis of modern national and foreign research on the creation of liposomal forms of quercetin and the evaluation of the efficacy of this drug delivery system in the treatment of oncological, cardiological, viral, and other diseases accompanied by oxidative stress. To search for sources of information for the study, open-access electronic resources of scientific periodicals were used. Results. The development of liposomal quercetin formulations enabled increased bioavailability and expanded administration options, including injection. The use of liposomal quercetin in complex cancer therapy increased tumor growth inhibition while reducing side effects in healthy tissues. To improve the efficacy of quercetin delivery to tissues, it was proposed to modify liposome surfaces with hyaluronic acid, mycophenolic acid, polyethylene glycol, and magnetic particles. The possibility of using other carriers for quercetin delivery was demonstrated, including solid lipid nanoparticles, gold nanoparticles, and polymers. Conclusions. Quercetin nanopreparations demonstrate high pharmacological efficacy and a significant increase in quercetin bioavailability, and their safety, biodegradability, and reduced toxicity are also important.